Ischaemic colitis associated with intravitreal administration of aflibercept: A first case report.
Br J Clin Pharmacol
; 85(4): 845-848, 2019 04.
Article
en En
| MEDLINE
| ID: mdl-30610744
ABSTRACT
In patients with age-related macular degeneration (AMD), the intravitreal injection of antivascular endothelial growth factor (anti-VEGF) agents reduces disease progression and choroidal neovascularization. We report on a first case of ischaemic colitis associated with intravitreal injection of the anti-VEGF agent aflibercept in an 80-year-old female patient. Conservative treatment resulted in a favourable clinical outcome. The anti-VEGF agent was discontinued, and the symptoms did not recur. Although the intravitreal injection of anti-VEGF agents has not previously been linked to the occurrence of ischaemic colitis, consideration of aflibercept's pharmacological properties and the chronological relationship between the administration of this anti-VEGF agent and the occurrence of this systemic adverse event are strongly suggestive of a causal relationship in the present case. Although systemic complications have been rarely associated with intravitreal injections of anti-VEGF agents, physicians should be aware that novel adverse events can still occur in AMD patients treated with anti-VEGF agents.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Proteínas Recombinantes de Fusión
/
Colitis Isquémica
/
Inhibidores de la Angiogénesis
/
Degeneración Macular
Tipo de estudio:
Diagnostic_studies
/
Risk_factors_studies
Límite:
Aged80
/
Female
/
Humans
Idioma:
En
Año:
2019
Tipo del documento:
Article